ZNF410

Summary

ZNF410 (zinc finger protein 410, HGNC:20144) is a protein-coding gene on chromosome 14q24.3, encoding Zinc finger protein 410 (Q86VK4). Transcription factor that binds to the sequence motif 5’-CATCCCATAATA-3’, and is specifically required to silence expression of fetal hemoglobin in adult erythroid cells.

Enables DNA-binding transcription factor activity and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in negative regulation of gene expression and positive regulation of transcription by RNA polymerase II. Predicted to be located in chromosome. Predicted to be active in nucleus.

Source: NCBI Gene 57862 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 56 total
• MANE Select transcript: NM_021188

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20144
Approved symbol	ZNF410
Name	zinc finger protein 410
Location	14q24.3
Locus type	gene with protein product
Status	Approved
Aliases	APA1, APA-1
Ensembl gene	ENSG00000119725
Ensembl biotype	protein_coding
OMIM	619427
Entrez	57862

Gene structure

Transcript identifiers

Ensembl transcripts: 47 — 39 protein_coding, 3 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000324593, ENST00000334521, ENST00000398139, ENST00000412490, ENST00000442160, ENST00000540593, ENST00000541357, ENST00000554316, ENST00000554582, ENST00000554797, ENST00000555044, ENST00000555602, ENST00000555620, ENST00000555730, ENST00000556160, ENST00000556179, ENST00000556396, ENST00000556659, ENST00000556797, ENST00000557214, ENST00000557495, ENST00000557679, ENST00000615736, ENST00000896480, ENST00000896481, ENST00000896482, ENST00000896483, ENST00000896484, ENST00000896485, ENST00000896486, ENST00000896487, ENST00000896488, ENST00000896489, ENST00000939733, ENST00000939735, ENST00000939737, ENST00000939738, ENST00000966298, ENST00000966299, ENST00000966300, ENST00000966301, ENST00000966302, ENST00000966303, ENST00000966304, ENST00000966305, ENST00000966306, ENST00000966307

RefSeq mRNA: 5 — MANE Select: NM_021188 NM_001242924, NM_001242926, NM_001242927, NM_001242928, NM_021188

CCDS: CCDS55929, CCDS55930, CCDS55931, CCDS9821

Canonical transcript exons

ENST00000555044 — 12 exons

Exon	Start	End
ENSE00002504534	73931503	73932521
ENSE00003466856	73903960	73904110
ENSE00003470013	73904902	73905083
ENSE00003479050	73922066	73922206
ENSE00003514619	73898071	73898262
ENSE00003538731	73920980	73921105
ENSE00003600680	73892027	73892208
ENSE00003636295	73893797	73893932
ENSE00003640597	73896316	73896534
ENSE00003667608	73909341	73909430
ENSE00003671624	73923395	73923522
ENSE00003899147	73886859	73886915

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 94.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.4945 / max 325.6449, expressed in 1809 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
140560	17.4309	1797
140561	2.7242	1464
140559	1.4495	680
140562	0.8429	305
140558	0.0470	13

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
islet of Langerhans	UBERON:0000006	94.25	gold quality
bone marrow	UBERON:0002371	94.16	gold quality
bone marrow cell	CL:0002092	94.12	gold quality
right testis	UBERON:0004534	93.82	gold quality
left testis	UBERON:0004533	93.80	gold quality
testis	UBERON:0000473	93.59	gold quality
ventricular zone	UBERON:0003053	93.47	gold quality
left ovary	UBERON:0002119	93.35	gold quality
ovary	UBERON:0000992	93.31	gold quality
smooth muscle tissue	UBERON:0001135	93.06	gold quality
endometrium	UBERON:0001295	93.01	gold quality
placenta	UBERON:0001987	92.97	gold quality
right ovary	UBERON:0002118	92.97	gold quality
skin of leg	UBERON:0001511	92.74	gold quality
adrenal tissue	UBERON:0018303	92.72	gold quality
zone of skin	UBERON:0000014	92.69	gold quality
ganglionic eminence	UBERON:0004023	92.69	gold quality
skin of abdomen	UBERON:0001416	92.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	92.47	gold quality
lower esophagus mucosa	UBERON:0035834	92.44	gold quality
tibial artery	UBERON:0007610	92.37	gold quality
popliteal artery	UBERON:0002250	92.36	gold quality
right adrenal gland cortex	UBERON:0035827	92.33	gold quality
right adrenal gland	UBERON:0001233	92.28	gold quality
left uterine tube	UBERON:0001303	92.27	gold quality
adrenal gland	UBERON:0002369	92.11	gold quality
myometrium	UBERON:0001296	91.94	gold quality
gall bladder	UBERON:0002110	91.94	gold quality
esophagus	UBERON:0001043	91.89	gold quality
lower esophagus	UBERON:0013473	91.88	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.37

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

6 targets.

Target	Regulation
CHD4	Activation
HBG1	Repression
HBG2	Repression
MMP1	Unknown
MT1A
TGFA

JASPAR motifs

Motif	Name	Family
MA0752.1	ZNF410	More than 3 adjacent zinc fingers
MA0752.2	ZNF410	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:19443739

miRNA regulators (miRDB)

34 targeting ZNF410, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-6516-3P	99.65	68.57	1238
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-642A-5P	99.51	65.10	1152
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-330-3P	99.41	69.95	2521
HSA-MIR-5697	99.39	67.74	1249
HSA-MIR-6506-5P	99.04	65.66	1386
HSA-MIR-6760-5P	98.87	66.73	1515
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-3192-3P	98.62	65.80	970
HSA-MIR-619-5P	98.57	64.97	1988
HSA-MIR-3928-5P	98.50	67.48	980
HSA-MIR-6806-3P	98.50	67.31	980
HSA-MIR-6516-5P	98.42	70.19	1551
HSA-MIR-5088-3P	98.29	66.63	1310
HSA-MIR-4675	97.69	64.82	774
HSA-MIR-4741	97.69	64.14	883
HSA-MIR-510-5P	97.66	65.82	916
HSA-MIR-3157-5P	97.41	67.61	998
HSA-MIR-383-5P	96.86	67.55	820
HSA-MIR-550B-2-5P	96.56	64.61	646
HSA-MIR-152-5P	96.42	66.59	960

Literature-anchored findings (GeneRIF, showing 6)

• APA1 has a role in inducing extracellular matrix remodeling genes (PMID:12370286)
• VDR polymorphism genotypes and haplotypes did not directly alter recurrence risk, but the reduction in risk associated with high dairy product intake was confined to individuals with ApaI aA/AA genotype. (PMID:18470879)
• No association was found between Apa1 genotypes and osteoporosis (PMID:26290023)
• The HG-stimulated proliferative capacity was abolished upon decreasing O-GlcNAcylation, which could be reversed gradually by the simultaneous overexpression of APA1 and GJC1. Therefore, GJC1 could be a potential target for preventing liver cancer in patients with diabetes. (PMID:30078215)
• ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression. (PMID:33301730)
• ZNF410 represses fetal globin by singular control of CHD4. (PMID:33859416)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf410	ENSDARG00000008218
mus_musculus	Zfp410	ENSMUSG00000042472
rattus_norvegicus	Zfp410	ENSRNOG00000010985

Paralogs (36): ZBTB32 (ENSG00000011590), SNAI2 (ENSG00000019549), PRDM1 (ENSG00000057657), PRDM6 (ENSG00000061455), ZNF76 (ENSG00000065029), PATZ1 (ENSG00000100105), MAZ (ENSG00000103495), ZBTB16 (ENSG00000109906), ZNF451 (ENSG00000112200), ZBTB45 (ENSG00000119574), SNAI1 (ENSG00000124216), ZNF384 (ENSG00000126746), ZBTB1 (ENSG00000126804), VEZF1 (ENSG00000136451), PRDM14 (ENSG00000147596), ZNF276 (ENSG00000158805), ZNF362 (ENSG00000160094), ZNF653 (ENSG00000161914), ZNF281 (ENSG00000162702), ZNF148 (ENSG00000163848), ZNF143 (ENSG00000166478), HIC2 (ENSG00000169635), PRDM10 (ENSG00000170325), ZNF296 (ENSG00000170684), ZNF692 (ENSG00000171163), ZNF575 (ENSG00000176472), HIC1 (ENSG00000177374), ZBTB18 (ENSG00000179456), ZBTB42 (ENSG00000179627), ZBTB20 (ENSG00000181722), ZBTB7C (ENSG00000184828), SNAI3 (ENSG00000185669), ZFP91 (ENSG00000186660), MTF1 (ENSG00000188786), SCRT2 (ENSG00000215397), SCRT1 (ENSG00000261678)

Protein

Protein identifiers

Zinc finger protein 410 — Q86VK4 (reviewed: Q86VK4)

Alternative names: Another partner for ARF 1

All UniProt accessions (12): Q86VK4, G3V2C2, G3V2G5, G3V2V5, G3V369, G3V398, G3V3W2, G3V4E6, G3V4H7, G3V4W2, H0YJI7, J3KNQ6

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that binds to the sequence motif 5’-CATCCCATAATA-3’, and is specifically required to silence expression of fetal hemoglobin in adult erythroid cells. Prevents expression of fetal hemoglobin genes HBG1 and HBG2 through CHD4: acts as a direct transcriptional activator of CHD4, a central component of the NuRD complex that represses transcription of fetal hemoglobin genes HBG1 and HBG2 in erythroid cells. May also activate transcription of matrix-remodeling genes such as MMP1 during fibroblast senescence. May activate transcription of the gap junction gene GJC1, perhaps in response to increasing glucose. However, recent studies suggest that ZNF410 is dedicated to regulate expression of a single gene: CHD4.

Subunit / interactions. Interacts with CDKN2A/p14ARF.

Subcellular location. Nucleus. Chromosome.

Tissue specificity. Widely expressed.

Post-translational modifications. Sumoylated. Sumoylation increases its half-life, possibly by blocking ubiquitin-mediated degradation. O-glycosylated. O-GlcNAcylation may occur in response to increasing glucose levels and affect transcription factor activity.

Domain organisation. The five zinc finger domains are necessary and sufficient to bind to DNA.

Induction. During fibroblast senescence.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (5)

UniProt ID	Names	Canonical?
Q86VK4-1	1	yes
Q86VK4-2	2
Q86VK4-3	3
Q86VK4-4	4
Q86VK4-5	5

RefSeq proteins (5): NP_001229853, NP_001229855, NP_001229856, NP_001229857, NP_067011* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096

UniProt features (48 total): binding site 20, splice variant 6, helix 6, zinc finger region 5, strand 5, turn 4, chain 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6WMI	X-RAY DIFFRACTION	2.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86VK4-F1	49.19	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (20): 243; 251; 256; 269; 273; 281; 286; 299; 303; 311; 316; 329 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 152 (showing top): MORF_RAB5A, MORF_PSMC2, MORF_RAF1, ONKEN_UVEAL_MELANOMA_UP, chr14q24, MARTINEZ_RB1_TARGETS_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, MORF_PPP6C, RYTTCCTG_ETS2_B, DANG_BOUND_BY_MYC, MARTINEZ_RB1_AND_TP53_TARGETS_UP, BROWNE_HCMV_INFECTION_14HR_UP, BENPORATH_MYC_MAX_TARGETS, SCGGAAGY_ELK1_02

GO Biological Process (6): regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of gene expression (GO:0010629), positive regulation of transcription by RNA polymerase II (GO:0045944), negative regulation of macromolecule biosynthetic process (GO:0010558), oxygen transport (GO:0015671), positive regulation of DNA-templated transcription (GO:0045893)

GO Molecular Function (9): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity (GO:0003700), transcription coregulator activity (GO:0003712), zinc ion binding (GO:0008270), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), chromosome (GO:0005694)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
transcription by RNA polymerase II	2
transcription regulator activity	2
gene expression	1
regulation of gene expression	1
negative regulation of macromolecule biosynthetic process	1
regulation of transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
macromolecule biosynthetic process	1
negative regulation of biosynthetic process	1
regulation of macromolecule biosynthetic process	1
negative regulation of macromolecule metabolic process	1
gas transport	1
DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
cis-regulatory region sequence-specific DNA binding	1
transcription cis-regulatory region binding	1
transition metal ion binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
DNA binding	1
cation binding	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

608 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF410	CDX2	Q99626	574
ZNF410	TFCP2	Q12800	545
ZNF410	CNOT1	A5YKK6	478
ZNF410	CYP2R1	Q6VVX0	445
ZNF410	CYP24A1	Q07973	431
ZNF410	CPA2	P48052	419
ZNF410	ST8SIA4	Q92187	400
ZNF410	GC	P02774	398
ZNF410	CPA1	P15085	394
ZNF410	SLC9A1	P19634	375
ZNF410	CYP27B1	O15528	369
ZNF410	C10orf88	Q9H8K7	348
ZNF410	ACAP3	Q96P50	347
ZNF410	CHD4	Q14839	331
ZNF410	MRM2	Q9UI43	328

IntAct

41 interactions, top by confidence:

A	B	Type	Score
BLZF1	ZNF410	psi-mi:“MI:0915”(physical association)	0.670
FSD2	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
GOLGA2	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
ZNF410	TRAF2	psi-mi:“MI:0915”(physical association)	0.560
SERTAD1	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
MTUS2	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
FAM9B	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
ZNF410	ZNF397	psi-mi:“MI:0915”(physical association)	0.560
CEP70	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
RAB3IP	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
ZNF410	TSGA10	psi-mi:“MI:0915”(physical association)	0.560
ZNF410	FSD2	psi-mi:“MI:0915”(physical association)	0.560
ZNF410	GOLGA2	psi-mi:“MI:0915”(physical association)	0.560
TRAF2	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
ZNF410	RAB3IP	psi-mi:“MI:0915”(physical association)	0.560
TSGA10	ZNF410	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (65): ZNF410 (Two-hybrid), ZNF410 (Two-hybrid), ZNF410 (Two-hybrid), ZNF410 (Two-hybrid), ZNF410 (Two-hybrid), CEP70 (Two-hybrid), TSGA10 (Two-hybrid), ZNF397 (Two-hybrid), RAB3IP (Two-hybrid), FSD2 (Two-hybrid), FAM9B (Two-hybrid), PNMA1 (Two-hybrid), DVL2 (Two-hybrid), PPP1R16B (Two-hybrid), ZNF410 (Two-hybrid)

ESM2 similar proteins: A0A1D5NS60, A0JN76, A1YFX5, A2T7G6, A6NJL1, D2HQI1, F1MJR8, O14901, P0CG00, P10754, P22227, P98182, Q0IJ29, Q1L8W0, Q3SWU4, Q5DW34, Q5EAC5, Q5EXX3, Q5RHB5, Q5SXI5, Q5T619, Q66H04, Q6NRM8, Q6NV66, Q6ZSB9, Q7M6U3, Q7TS63, Q7TSH3, Q7ZWZ4, Q801P1, Q86VK4, Q8BKX7, Q8BXX2, Q8NAM6, Q8NAP3, Q8NCP5, Q8R0A2, Q91VW9, Q96IT1, Q96N77

Diamond homologs: Q5EAC5, Q86VK4, Q8BKX7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2483 predictions. Top by Δscore:

Variant	Effect	Δscore
14:73892021:TTCTA:T	acceptor_loss	1.0000
14:73892022:TCTA:T	acceptor_loss	1.0000
14:73892024:TA:T	acceptor_loss	1.0000
14:73892024:TAGGT:T	acceptor_loss	1.0000
14:73892025:A:T	acceptor_loss	1.0000
14:73892026:G:A	acceptor_loss	1.0000
14:73898068:CAGGT:C	acceptor_loss	1.0000
14:73898069:A:AC	acceptor_loss	1.0000
14:73898070:G:GT	acceptor_loss	1.0000
14:73904111:G:GG	donor_gain	1.0000
14:73904204:A:T	donor_gain	1.0000
14:73904899:CA:C	acceptor_loss	1.0000
14:73904900:A:AC	acceptor_loss	1.0000
14:73904900:A:AG	acceptor_gain	1.0000
14:73904901:G:GA	acceptor_gain	1.0000
14:73904901:G:GC	acceptor_loss	1.0000
14:73904901:G:GG	acceptor_gain	1.0000
14:73904901:GA:G	acceptor_gain	1.0000
14:73904901:GAA:G	acceptor_gain	1.0000
14:73904901:GAAA:G	acceptor_gain	1.0000
14:73904901:GAAAT:G	acceptor_gain	1.0000
14:73905080:ACAGG:A	donor_loss	1.0000
14:73905081:CAGG:C	donor_loss	1.0000
14:73905082:AGG:A	donor_loss	1.0000
14:73905082:AGGTG:A	donor_loss	1.0000
14:73905084:G:C	donor_loss	1.0000
14:73905084:GTGT:G	donor_loss	1.0000
14:73905085:T:A	donor_loss	1.0000
14:73920961:AACCT:A	acceptor_gain	1.0000
14:73921082:G:GT	donor_gain	1.0000

AlphaMissense

3115 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:73904921:T:C	C251R	1.000
14:73904948:T:C	F260L	1.000
14:73904950:C:A	F260L	1.000
14:73904950:C:G	F260L	1.000
14:73905011:T:C	C281R	1.000
14:73905038:T:C	F290L	1.000
14:73905039:T:C	F290S	1.000
14:73905040:T:A	F290L	1.000
14:73905040:T:G	F290L	1.000
14:73909358:T:C	C311R	1.000
14:73909385:T:C	F320L	1.000
14:73909387:T:A	F320L	1.000
14:73909387:T:G	F320L	1.000
14:73920997:T:C	C341R	1.000
14:73921018:T:C	F348L	1.000
14:73921020:C:A	F348L	1.000
14:73921020:C:G	F348L	1.000
14:73904040:T:A	C221S	0.999
14:73904040:T:C	C221R	0.999
14:73904041:G:C	C221S	0.999
14:73904042:T:G	C221W	0.999
14:73904067:T:C	F230L	0.999
14:73904068:T:C	F230S	0.999
14:73904069:T:A	F230L	0.999
14:73904069:T:G	F230L	0.999
14:73904921:T:A	C251S	0.999
14:73904922:G:C	C251S	0.999
14:73904923:T:G	C251W	0.999
14:73904936:T:A	C256S	0.999
14:73904936:T:C	C256R	0.999

dbSNP variants (sampled 300 via entrez): RS1000032322 (14:73914924 G>A), RS1000102421 (14:73910384 T>C), RS1000104317 (14:73901997 A>C,G), RS1000221862 (14:73897299 T>G), RS1000307244 (14:73910057 A>G), RS1000371674 (14:73897685 G>A), RS1000424252 (14:73905443 C>T), RS1000570344 (14:73905389 A>G), RS1000686230 (14:73891801 T>C), RS1000753916 (14:73899013 A>G), RS1000759535 (14:73890546 T>C), RS1000817371 (14:73917068 T>G), RS1000820479 (14:73930638 C>T), RS1000823383 (14:73891535 G>A), RS1000849871 (14:73916792 A>G)

Disease associations

OMIM: gene MIM:619427 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005557_1	Serum uric acid levels	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004761	uric acid measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
Cyclosporine	increases expression	2
FR900359	increases phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
TAK-243	increases sumoylation	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
geraniol	increases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
K 7174	increases expression	1
abrine	increases expression	1
PCI 5002	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Cadmium	increases abundance, increases expression	1
Carbamazepine	affects expression	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Dimethyl Sulfoxide	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Methotrexate	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Phenobarbital	affects expression	1
Plant Extracts	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.